This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pluristem Selects Fisher BioServices As Worldwide Dispatch Distributor Of Its PLX Cell Therapies To Serve Global Clinical Studies

Stocks in this article: PSTI

HAIFA, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has selected Fisher BioServices, Inc. as worldwide dispatch distributor of its off-the-shelf PLacental eXpanded (PLX) cells. Fisher BioServices will provide cryogenic storage and distribution of Pluristem's PLX cells for its clinical trials and preclinical sites around the world.

Pluristem currently is targeting several therapeutics indications for which clinical trials and preclinical studies are in progress, which include: a) intermittent claudication; b) muscle regeneration c) critical limb ischemia d) Buerger's disease; and e) acute radiation syndrome. The different studies are scheduled to take place in Europe, India, Israel and the U.S. In addition, Pluristem has reported strong pre-clinical study results in other indications for which the company may pursue clinical trials in the future. These include the treatment of acute myocardial infarction (heart attack), lung disease, and bone marrow disease. These indications collectively represent multibillion dollar treatment markets.

Fisher BioServices is the world's leading provider of specialized biological sample and material management, and cell therapy logistics services to pharmaceutical and biotech companies, and national, state and academic institutions. Equipped to provide storage and cold chain transportation capabilities for the entire spectrum of cell-based and regenerative medicine worldwide, Fisher BioServices also provides distribution of cell-based therapies from manufacturer to patient bedside, with complete chain of custody documentation.

"As we expand our roster of clinical trials for our PLX cell therapies for several indications, we needed a reliable leader in cell therapy distribution. Fisher BioServices was the clear choice for us because they are the world's leader in biological materials handling and have supported hundreds of clinical trials," said Zami Aberman, Chairman and CEO of Pluristem.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs